Sanofi announced on July 30, 2026, that its half-year financial report for the period ending June 30, 2026, is now available to investors. This filing ensures transparency for shareholders listed on both EURONEXT and NASDAQ, providing timely access to the company’s financial performance for the first half of the year.

The report has been officially filed with the Autorité des marchés financiers (AMF), the French market regulator, and submitted to the US Securities and Exchange Commission (SEC) under Form 6-K. These regulatory submissions comply with international disclosure requirements for multinational corporations operating in both European and American markets.

Document Availability

Investors and analysts can access the full financial report through Sanofi’s corporate website. The document is located on the "Investors" page under the specific heading "Financial Reports and Other Publications." This centralised repository allows stakeholders to download the latest financial data directly without intermediary delays.

About Sanofi

Sanofi describes itself as an R&D-driven, AI-powered biopharma company committed to improving people’s lives. The company focuses on inventing medicines and vaccines that treat and protect millions globally, leveraging a deep understanding of the immune system. Its innovative pipeline aims to address urgent healthcare, environmental, and societal challenges.

The company is listed on EURONEXT under the ticker SAN and on NASDAQ under the ticker SNY. For further inquiries, investors may contact the Investor Relations team, including Thomas Kudsk Larsen, Alizé Kaisserian, Keita Browne, Nathalie Pham, Nina Goworek, Thibaud Châtelet, and Yun Li.

Sanofi reported full-year sales of $55.789 billion for FY2026, missing the consensus analyst estimate of $55.850 billion. The slight shortfall highlights the pressure on the pharmaceutical giant to meet market expectations in a competitive global landscape.

The filing discloses that total sales for the fiscal year ended at $55.789 billion. Analysts had projected a higher figure of $55.850 billion, indicating a modest gap between actual performance and market sentiment.

Financial Performance

The difference between the reported sales and the estimate is minimal, suggesting that operational execution remained largely in line with broader market forecasts despite the technical miss.

What the Numbers Show

The narrow miss of $0.061 billion suggests that while Sanofi’s core business drivers performed as expected, specific segment variances or pricing pressures may have prevented the company from crossing the consensus threshold. Investors will likely focus on whether this slight deviation impacts future guidance or reflects a one-off timing issue.